MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Motor Responses to Apomorphine Sublingual Film Compared With Levodopa in Patients With Parkinson’s Disease and “OFF” Episodes: Post Hoc Analysis From a Phase 3 Study

J. Hui, S. Fox, W. Neeson, P. Bhargava, E. Pappert, D. Blum, B. Navia (Los Angeles, CA, USA)

Meeting: 2019 International Congress

Abstract Number: 899

Keywords: Apomorphine, Parkinsonism, Wearing-off fluctuations

Session Information

Date: Tuesday, September 24, 2019

Session Title: Parkinsonisms and Parkinson-Plus

Session Time: 1:45pm-3:15pm

Location: Agora 3 West, Level 3

Objective: To compare time to onset and magnitude of motor improvement following administration of apomorphine sublingual film (APL-130277; APL) vs levodopa in patients with Parkinson’s disease (PD) and “OFF” episodes.

Background: APL was found to be effective and generally well tolerated as an acute, intermittent treatment for “OFF” episodes in patients with PD in a controlled Phase 3 trial.

Method: Adult patients with PD and “OFF” episodes receiving levodopa were enrolled into this Phase 3 trial. At screening, patients in a clinically defined “OFF” state were observed for a FULL “ON” response following their normal morning levodopa dose. During open-label titration, patients received 10–35 mg of APL in 5-mg increments per day until a FULL “ON” response was achieved without intolerable side effects. In this post hoc analysis, motor responses following open-label APL and levodopa administration (n=109) were compared by descriptive statistics using the Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III score assessed predose, and 15, 30, 45, 60, and 90 minutes postdose.

Results: One hundred nine and 108 patients treated with APL and levodopa, respectively, were analyzed. Predose MDS-UPDRS Part III scores were comparable at screening and titration (43.5 vs 43.1). The magnitude of motor response with APL was ~2-fold higher than with levodopa (-12.6 vs -6.0) at 15 minutes postdose and the observed mean response to APL was greater through 45 minutes postdose. Peak response to APL occurred earlier (45 minutes) than with levodopa (90 minutes), and the magnitude of peak responses was comparable (-26.1 vs -27.9). Responder (defined as a ≥30% decrease in MDS-UPDRS Part III score from predose) rates were 43% vs 18% at 15 minutes and 93% vs 50% at 30 minutes for APL and levodopa, respectively.

Conclusion: APL was associated with an earlier onset of motor improvement and earlier peak response vs levodopa in patients with PD and “OFF” episodes. Responder rates were also higher with APL while the magnitude of peak response was similar between APL and levodopa.

To cite this abstract in AMA style:

J. Hui, S. Fox, W. Neeson, P. Bhargava, E. Pappert, D. Blum, B. Navia. Motor Responses to Apomorphine Sublingual Film Compared With Levodopa in Patients With Parkinson’s Disease and “OFF” Episodes: Post Hoc Analysis From a Phase 3 Study [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/motor-responses-to-apomorphine-sublingual-film-compared-with-levodopa-in-patients-with-parkinsons-disease-and-off-episodes-post-hoc-analysis-from-a-phase-3-study/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/motor-responses-to-apomorphine-sublingual-film-compared-with-levodopa-in-patients-with-parkinsons-disease-and-off-episodes-post-hoc-analysis-from-a-phase-3-study/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley